Decreased placental growth factor levels precede the onset of gestational diabetes mellitus: Insights into placental dysfunction and endothelial pathophysiology.
PlGF levels were lower in women with gestational diabetes compared to controls, but the clinical significance of this finding is not clear.
Where it sits
this study against the rest of the pe 22-28 corpusSummary and findings
This study measured serum levels of placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1) in 830 pregnant women to investigate their relationship with gestational diabetes mellitus (GDM). PlGF levels were significantly lower in the GDM group compared to controls, with median values of 231 pg/mL versus 260 pg/mL, p=0.05. No significant differences were found for sFlt-1 levels or the sFlt-1/PlGF ratio.
Abstract
<h4>Aims</h4>Gestational diabetes mellitus (GDM) and preeclampsia (PE) are obstetric complications that share common pathophysiological features involving endothelial dysfunction. Previous studies suggest that GDM increases PE risk. While the roles of soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) are well-established in PE, their involvement in GDM remains unclear. To address this gap, we conducted a retrospective cohort study measuring serum levels of sFlt-1, PlGF, and their ratio before the diagnosis of GDM.<h4>Methods</h4>This study analyzed 830 pregnant women who underwent serum sFlt-1 and PlGF measurements between 18 and 22 weeks of gestation. GDM diagnosis was performed between approximately 22 - 28 weeks of gestation using a 75g OGTT, and patients were classified into GDM and control groups.<h4>Results</h4>PlGF levels were significantly lower in the GDM group than in the control group (median values: 231 vs. 260 pg/mL, p = 0.05). Conversely, no statistically significant differences were observed between the GDM and control groups in terms of serum sFlt-1 levels and the sFlt-1/PlGF ratio.<h4>Conclusions</h4>These findings suggest that PlGF may play a crucial role in GDM pathophysiology and that an imbalance between sFlt-1 and PlGF may be more pronounced in severe GDM.
Background
This paper addresses the clinical question of how placental growth factor levels relate to the development of gestational diabetes mellitus (GDM). Prior research has indicated that placental dysfunction may play a role in GDM, but the timing and nature of these changes have not been thoroughly elucidated. Understanding these dynamics is crucial for identifying potential early biomarkers for GDM.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Key findings
- Not reported in abstract.
Limitations
- Not reported in abstract.